Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 27:13:954804.
doi: 10.3389/fimmu.2022.954804. eCollection 2022.

Natural killer cells: the next wave in cancer immunotherapy

Xin Chen  1 , Lei Jiang  1 , Xuesong Liu  1
Affiliations
Review

Natural killer cells: the next wave in cancer immunotherapy

Xin Chen et al. Front Immunol. .

Abstract

Immunotherapies focusing on rejuvenating T cell activities, like PD-1/PD-L1 and CTLA-4 blockade, have unprecedentedly revolutionized the landscape of cancer treatment. Yet a previously underexplored component of the immune system - natural killer (NK) cell, is coming to the forefront of immunotherapeutic attempts. In this review, we discuss the contributions of NK cells in the success of current immunotherapies, provide an overview of the current preclinical and clinical strategies at harnessing NK cells for cancer treatment, and highlight that NK cell-mediated therapies emerge as a major target in the next wave of cancer immunotherapy.

Keywords: NK cell therapy; cancer; iPSC-NK; immune checkpoint; immunotherapy; natural killer (NK) cells.

PubMed Disclaimer

Conflict of interest statement

XC is a Senior Principal Investigator at the company BeiGene (Beijing) Co., Ltd. LJ is a Senior Scientist at the company BeiGene (Beijing) Co., Ltd. XL is the Vice President, Head of Biology at the company BeiGene (Beijing) Co., Ltd.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol (2018) 18:671–88. doi: 10.1038/s41577-018-0061-z - DOI - PubMed
    1. Trinchieri G. Biology of natural killer cells. Adv Immunol (1989) 47:187–376. doi: 10.1016/s0065-2776(08)60664-1 - DOI - PMC - PubMed
    1. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol (2007) 7:703–14. doi: 10.1038/nri2154 - DOI - PubMed
    1. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol (2013) 31:227–58. doi: 10.1146/annurev-immunol-020711-075005 - DOI - PMC - PubMed
    1. Roder JC, Haliotis T, Klein M, Korec S, Jett JR, Ortaldo J, et al. . A new immunodeficiency disorder in humans involving NK cells. Nature (1980) 284:553–5. doi: 10.1038/284553a0 - DOI - PubMed

Publication types